Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Brugia malayi | Integrin beta pat-3 precursor | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Echinococcus granulosus | integrin beta 2 | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Loa Loa (eye worm) | integrin beta-2 | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Schistosoma japonicum | Integrin beta-3 precursor, putative | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Echinococcus multilocularis | integrin beta 2 | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Schistosoma mansoni | integrin beta subunit | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Schistosoma japonicum | ko:K06464 integrin beta 2, putative | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Schistosoma japonicum | Integrin beta-PS precursor, putative | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.0181 | 0.2018 | 0.5 |
Echinococcus granulosus | integrin beta 2 | 0.028 | 0.6043 | 0.842 |
Plasmodium falciparum | eukaryotic initiation factor 4A | 0.0143 | 0.0524 | 0.5 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.0301 | 0.6869 | 0.9706 |
Schistosoma mansoni | hypothetical protein | 0.0214 | 0.3366 | 0.4336 |
Treponema pallidum | ATP-dependent RNA helicase | 0.0143 | 0.0524 | 0.5 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0306 | 0.7078 | 1 |
Giardia lamblia | Hypothetical protein | 0.0181 | 0.2018 | 1 |
Plasmodium vivax | RNA helicase-1, putative | 0.0143 | 0.0524 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0306 | 0.7078 | 0.6916 |
Schistosoma mansoni | 6-phosphofructokinase | 0.0306 | 0.7078 | 1 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0143 | 0.0524 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0306 | 0.7078 | 1 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0301 | 0.6869 | 0.9706 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0306 | 0.7078 | 1 |
Brugia malayi | Inhibitor of Apoptosis domain containing protein | 0.0214 | 0.3366 | 0.2998 |
Leishmania major | eukaryotic initiation factor 4a, putative | 0.0143 | 0.0524 | 0.0741 |
Echinococcus granulosus | baculoviral IAP repeat containing protein | 0.0214 | 0.3366 | 0.4336 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0301 | 0.6869 | 0.9706 |
Loa Loa (eye worm) | hypothetical protein | 0.0214 | 0.3366 | 0.2998 |
Onchocerca volvulus | 0.0306 | 0.7078 | 1 | |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0143 | 0.0524 | 0.5 |
Onchocerca volvulus | Deterin homolog | 0.0214 | 0.3366 | 0.4336 |
Echinococcus multilocularis | inhibitor of apoptosis protein | 0.0214 | 0.3366 | 0.4336 |
Loa Loa (eye worm) | hypothetical protein | 0.0175 | 0.181 | 0.1357 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0306 | 0.7078 | 1 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.0306 | 0.7078 | 1 |
Echinococcus granulosus | inhibitor of apoptosis protein | 0.0214 | 0.3366 | 0.4336 |
Mycobacterium tuberculosis | Probable cold-shock DeaD-box protein A homolog DeaD (ATP-dependent RNA helicase dead homolog) | 0.0143 | 0.0524 | 0.5 |
Loa Loa (eye worm) | integrin beta-2 | 0.0378 | 1 | 1 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.0181 | 0.2018 | 1 |
Echinococcus multilocularis | integrin beta 2 | 0.028 | 0.6043 | 0.842 |
Loa Loa (eye worm) | hypothetical protein | 0.0301 | 0.6869 | 0.6696 |
Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0143 | 0.0524 | 0.0741 |
Toxoplasma gondii | eukaryotic initiation factor-4A, putative | 0.0143 | 0.0524 | 0.5 |
Leishmania major | eukaryotic initiation factor 4a, putative | 0.0143 | 0.0524 | 0.0741 |
Echinococcus multilocularis | baculoviral IAP repeat containing protein | 0.0214 | 0.3366 | 0.4336 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0143 | 0.0524 | 0.5 |
Brugia malayi | Inhibitor of Apoptosis domain containing protein | 0.0214 | 0.3366 | 0.2998 |
Onchocerca volvulus | 0.0214 | 0.3366 | 0.4336 | |
Loa Loa (eye worm) | hypothetical protein | 0.0214 | 0.3366 | 0.2998 |
Schistosoma mansoni | inhibitor of apoptosis (iap) domain family member | 0.0214 | 0.3366 | 0.4336 |
Schistosoma mansoni | inhibitor of apoptosis protein | 0.0214 | 0.3366 | 0.4336 |
Trypanosoma brucei | Eukaryotic initiation factor 4A-1 | 0.0143 | 0.0524 | 0.0741 |
Giardia lamblia | Hypothetical protein | 0.0181 | 0.2018 | 1 |
Echinococcus granulosus | 6 phosphofructo 2 kinase:fructose 2 | 0.0306 | 0.7078 | 1 |
Schistosoma mansoni | integrin beta subunit | 0.0223 | 0.3723 | 0.4881 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0301 | 0.6869 | 0.9706 |
Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0143 | 0.0524 | 0.0741 |
Mycobacterium ulcerans | hypothetical protein | 0.0181 | 0.2018 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 5000 nM | Inhibitory concentration against alphaV-beta3 integrin using vitronectin ELISA assay. | ChEMBL. | 12482416 |
IC50 (binding) | = 5000 nM | Inhibitory concentration against alphaV-beta3 integrin using vitronectin ELISA assay. | ChEMBL. | 12482416 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.